Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Gbathaton Jan 10, 2025 12:32pm
96 Views
Post# 36398253

RE:RE:RE:Phase 1b

RE:RE:RE:Phase 1b Seems great.  Based on their past behavior, I'd suspect a partnership approach.  Unless they are just exhausted and ready to cash out themselves.  But I feel like the technical dev team has always been interested more in the technical and humanitarian outcome than the financial outcome, which has probably impacted previous decisions when sharks were initially circling.  They have sort of gone it alone in order to preserve their ownership and control... not an easy path amidst a mine field of over-promising competitors that sucked up lots of investor money and brought bid prices down.  

On my end, I'm not punching a clock (hopefully, lol), so my hope is that they see it through as ProMIS Inc and turn into the next big pharma company themselves.  Lots of great products in the pipe.  The AD market is the biggest opportunity space by far.

2025 is going to be a wild ride for them and us.  Buckle up.   

Thanks for sharing some of your dd here.  I really appreciate it.
<< Previous
Bullboard Posts
Next >>